Skip to main content

Relmada Therapeutics (NASDAQ: RLMD) — Company Overview, News & Financial Data

Relmada Therapeutics logo
RLMD Relmada Therapeutics
Relmada Therapeutics primary media
Company profile

Relmada Therapeutics

Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biotech company focused on developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to depression and other psychiatric disorders. Their portfolio includes multiple innovative projects aiming to address the unmet medical needs in mental health and pain management. One of their flagship products, REL-1017, is an NMDA receptor antagonist currently in advanced clinical trials for major depressive disorder, showcasing their commitment to pioneering treatments that can improve patient outcomes. With a clear objective to revolutionize the landscape of psychiatric and neurological care, Relmada Therapeutics is dedicated to advancing its research and development efforts to bring new, effective therapeutic options to market.

Snapshot

Public USOwnership
2012Year founded
20Employees
Coral Gables, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Coral Gables, US

Products and/or services of Relmada Therapeutics

  • Relmioram, a novel NMDA receptor antagonist for major depressive disorder, in Phase 3 clinical trials.
  • Development of therapies targeting central nervous system (CNS) diseases, including chronic pain.
  • Exploration of novel formulations and delivery methods for enhanced drug efficacy and patient compliance.
  • Investigations into potential treatments for neuropathic pain.

Relmada Therapeutics executive team

  • Sergio TraversaCEO & Director
  • Maged S. ShenoudaChief Financial Officer
  • Paul E. KellyCOO & Director
  • Charles S. EnceChief Accounting & Compliance Officer
  • Gina DiGuglielmoVP & Head of Clinical Operations
  • Bipin K. DalmiaChief Business Officer
  • Andrew CutlerSenior Clinical Development Advisor
  • Richard M. ManganoConsultant

Recent announcements

What Relmada Therapeutics (RLMD) has told the market, newest first.

Key financials

Reported results for Relmada Therapeutics, in USD.

Market cap
331.8M
Revenue (TTM)
0
P/E ratio
—
EPS (diluted, TTM)
-0.7
Dividend yield
—
Profit margin
0.0%
Relmada Therapeutics annual revenue and income
Fiscal year endRevenueOperating incomeNet income
0-59.1M-57.4M
0-83.9M-80M
0-103.7M-98.8M
0-161.2M-157M